Share this video  

SABCS 2023 | Trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel metastatic HER2+ breast cancer

Akihiko Shimomura, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, tells us more about the COG1607 HERB TEA study – a Phase III study which compared trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with metastatic HER2-positive breast cancer. One of the major challenges in treating older patients is the difficulty in maintaining a relative dose intensity, which often impairs quality of life. This study showed that treatment with trastuzumab emtansine was not inferior to the triple combination therapy in terms of overall survival. However, trastuzumab emtansine showed better tolerability in the frequency and severity of adverse events. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.